These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

684 related items for PubMed ID: 21892216

  • 21. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
    Harrington AR, Armstrong EP, Nolan PE, Malone DC.
    Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134
    [Abstract] [Full Text] [Related]

  • 22. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B, Faille D, Ajzenberg N.
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [Abstract] [Full Text] [Related]

  • 23. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ.
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P.
    Clin Ther; 2014 Feb 01; 36(2):192-210.e20. PubMed ID: 24508420
    [Abstract] [Full Text] [Related]

  • 28. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
    Eriksson BI, Quinlan DJ, Eikelboom JW.
    Annu Rev Med; 2011 Feb 01; 62():41-57. PubMed ID: 21226611
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
    Contractor T, Levin V, Martinez MW, Marchlinski FE.
    Postgrad Med; 2013 Jan 01; 125(1):34-44. PubMed ID: 23391669
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
    Truffa AA, Lopes RD, Newby LK.
    Postgrad Med; 2013 Mar 01; 125(2):146-57. PubMed ID: 23816780
    [Abstract] [Full Text] [Related]

  • 36. Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
    Yoon CH, Park YK, Kim SJ, Lee MJ, Ryoo S, Kim GM, Chung CS, Lee KH, Kim JS, Bang OY.
    Stroke; 2014 Oct 01; 45(10):2983-8. PubMed ID: 25147329
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
    Morell J, Sullivan B, Khalabuda M, McBride BF.
    J Clin Pharmacol; 2010 Sep 01; 50(9):986-1000. PubMed ID: 20124518
    [Abstract] [Full Text] [Related]

  • 39. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I.
    J Med Econ; 2014 Aug 01; 17(8):587-98. PubMed ID: 24831811
    [Abstract] [Full Text] [Related]

  • 40. Novel oral anticoagulants: a review of new agents.
    Wanat MA.
    Postgrad Med; 2013 Jul 01; 125(4):103-14. PubMed ID: 23933899
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.